Novelion Therapeutics Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Novelion Therapeutics (NVLN) Posts Q2 Loss of $0.08 on Revenue of $40.9M
August 8, 2017 7:14 AM EDTNovelion Therapeutics (NASDAQ: NVLN) reported Q2 EPS of ($0.08). Revenue was $40.9 million compared to the prior years second quarter net revenues of $0
2017 Financial Guidance
The Company is revising its previously stated net revenues financial guidance for full year 2017 and now expects:
Total net... More